EC Number |
Application |
Reference |
---|
1.3.1.2 | analysis |
study on DPD enzyme expression using RT-PCR, immunohistochemistry, enzymatic activity and ELISA. Highest correlation is observed between protein expression measured by ELISA and enzyme activity, correlation of gene expression and ELISA is also significant |
700526 |
1.3.1.2 | drug development |
the enzyme is an adjunct target in cancer therapy since it rapidly breaks down the anti-cancer drug 5-fluorouracil and related compounds |
711309 |
1.3.1.2 | medicine |
development of a HPLC method, sufficient, accurate, fast and sensitive to be applied to the analysis of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in plasma and cytoplasmic samples, allowing accurate pharmacokinetic analyses and measurements of dihydropyrimidine dehydrogenase in patients who are candidates for fluoropyrimidine-based chemotherapy without the need of a labeled substrate for enzyme studies |
670929 |
1.3.1.2 | medicine |
identification of mutants G366A and T768K in healthy Japanese volunteers. G366A results in marked decrease in enzyme affinity to NADPH, reduction of Vmax for 5-fluorouracil degrading activity, T768K leads to rapid loss of enzyme activity |
673116 |
1.3.1.2 | medicine |
identification of mutations E244V and A551T and splice site mutation IVS11+1G to T in patients with complete loss of enzymic activity |
672471 |
1.3.1.2 | medicine |
rate limiting enzyme for detoxification of exogenous fluoropyrimidines, antitumor drug design |
349213, 349220 |
1.3.1.2 | medicine |
rate limiting enzyme in catabolic degradation of pyrimidine derivatives, selective inhibition is strategy for design of antitumor, antimicrobial and potentially antiparasitic agents |
349218 |
1.3.1.2 | medicine |
target for inhibitor design to enhance the cytotoxical effect of 5-fluorouracil in tumor cells by inhibiting the DPD activity with 5-fluorouracil as substrate |
349142, 349143, 349235 |
1.3.1.2 | medicine |
uracil breath test breath 13CO2 pharmacokinetics parallel plasma [2-13C]uracil and [2-13C]dihydrouracil pharmacokinetics and are an accurate measure of interindividual variation in enzyme activity. Data support the use of uracil breath test to identify enzyme deficiency before 5-fluorouracil-based therapy |
673121 |